Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00131118 · ClinicalTrials.gov registry record · Phase 2
Zoledronic Acid in Children (1 -17 Years) With Severe Osteogenesis Imperfecta
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 127
- Enrollment target
NCT00131118 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 127 participants.
The verdict
NCT00131118, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 127 participants
- Enrollment target
Study Summary
This is an extension study to examine the long-term safety and efficacy of zoledronic acid in patients who have completed the core CZOL446H2202 study.
Interventions
- DRUG Zoledronic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2004-07 |
| Est. Completion | 2007-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00131118
The ClinicalTrials.gov registry entry for NCT00131118 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Zoledronic Acid is the first listed.
NCT00131118 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00131118 about?
NCT00131118 is a clinical study titled "Zoledronic Acid in Children (1 -17 Years) With Severe Osteogenesis Imperfecta". This is an extension study to examine the long-term safety and efficacy of zoledronic acid in patients who have completed the core CZOL446H2202 study.
What is the current status of trial NCT00131118?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 127 participants. The study started on 2004-07. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00131118?
The interventions under investigation include: Zoledronic Acid (DRUG).
Who is sponsoring clinical trial NCT00131118?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.